Kirkey, D., Summers, C., Tarlock, K., Huang, B., Hawkins, G., Panahi, N., Blankenfeld, M., Lira, I., Liu, B., Shin, S., Ries, R., Peplinski, J. H., Manni, S., Falco, P. D., Angelis, B. D., Quintarelli, C., Locatelli, F., Li, W., Meshinchi, S. (2025). CLEC2A, a validated cancer-specific antigen, is an ideal candidate for immunotherapeutic targeting in KMT2A-rearranged AML. Blood. https://doi.org/10.1182/blood-2025-4123